



# SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

( 深圳市海普瑞藥業集團股份有限公司 )

(A joint stock company incorporated in the People's Republic of China with limited liability)

(於中華人民共和國註冊成立的股份有限公司)

(Stock code 股份代號 : 9989)

## NOTIFICATION LETTER 通知信函

Dear Shareholders (附註1),

December 18, 2023

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "Company")

- Notice of publication of Circular, Notice and Proxy Form of the 2024 First Extraordinary General Meeting (the "Current Corporate Communications")

The Board of Directors of the Company has decided to convene the Company's 2024 First Extraordinary General Meeting (the "Meeting") at the HKE's e-Service Center, Yee Yue Centre, 17/F, Fa Fa Finance Centre, 16 Haxi Road, Hong Kong. The meeting will be held on December 20, 2023 at 9:00 a.m. to 6:00 p.m. (Mandarin Chinese). The agenda of the Meeting is as follows:

If you are unable to attend the Meeting in person, you may appoint a proxy to attend on your behalf. To do so, you need to complete the Request Form (附註2) and submit it to the Company's Corporate Secretary, Li Li, at the address above. The Request Form must be submitted to the Company's Corporate Secretary, Li Li, at the address above by 5:00 p.m. on December 19, 2023. The Request Form must be submitted to the Company's Corporate Secretary, Li Li, at the address above by 5:00 p.m. on December 19, 2023. The Request Form must be submitted to the Company's Corporate Secretary, Li Li, at the address above by 5:00 p.m. on December 19, 2023.

Unless otherwise specified, all the above information is in Chinese.

Should you have any questions, please contact the Company's Corporate Secretary, Li Li, at the address above by telephone at (852) 2980 1333 from 9:00 a.m. to 6:00 p.m. (Mandarin Chinese).

Yours faithfully,  
Faded signature  
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.  
Li Li  
Chairman

Note 1: The Company is a joint stock company incorporated in the People's Republic of China with limited liability. The Company's shares are listed on the Hong Kong Stock Exchange (the "Stock Exchange") under the listing code of 9989. The Company's corporate information is available on the Company's website (www.hepalink.com) and the Hong Kong Stock Exchange's website (www.hkex.com.hk).

Note 2: The Request Form is a form for appointing a proxy to attend the Meeting on behalf of the shareholder. The Request Form must be completed and submitted to the Company's Corporate Secretary, Li Li, at the address above by 5:00 p.m. on December 19, 2023. The Request Form must be submitted to the Company's Corporate Secretary, Li Li, at the address above by 5:00 p.m. on December 19, 2023. The Request Form must be submitted to the Company's Corporate Secretary, Li Li, at the address above by 5:00 p.m. on December 19, 2023.

致非登記股份持有人(附註1):

深圳市海普瑞藥業集團股份有限公司(「本公司」)  
- 2024年第一次臨時股東大會通函、通告及代表委任表格(「本次公司通訊文件」)之發佈通知

本公司的本次公司通訊文件中、英文版本現已上載於本公司網站www.hepalink.com及香港交易所披露易網站www.hkex.com.hk，歡迎瀏覽。請在本公司網站主頁的「投資者專區」項下選擇有關文件或在香港交易所披露易網站瀏覽有關文件。

如閣下欲收取本公司本次及將來所有公司通訊文件(附註2)之印刷本，請填妥在本信函背面的申請表格(「申請表格」)(該表格亦可於上述網站下載)，並使用申請表格下方的預付費郵寄標籤寄回(如在香港投寄)；否則，請貼上足夠的郵票。申請表格請經卓佳證券登記有限公司(「香港股份登記處」)寄回本公司，香港股份登記處的地址為香港夏慤道16號遠東金融中心17樓。

抽吳頌脫露 蒿郎鐘合 出掉蛸 掉普枯，鵲駟 備 豈 冉

